The BioPharm Brief: Bispecifics, Breakthroughs, and Business Decisions

Jul 24, 08:00 PM
Headliner
Share
Subscribe

This episode covers encouraging Phase 3 data for dual bispecific therapy in multiple myeloma, new preclinical evidence supporting CD24-targeted immunotherapy, and Sanofi's decision to discontinue amlitelimab for atopic dermatitis following a strategic pipeline review.

Share
Subscribe
Next
The BioPharm Brief: Reduction, Reach, and Reinforcement
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Regulatory Shifts, Rare Disease Innovation, and Precision Drug Development Trends
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief